idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Idiopathic%20pulmonary%20fibrosis Management

Follow Up

  • Follow-up is recommended every 3 months for patients with rapid disease progression or health status deterioration
  • Six-month intervals for follow-up is recommended for patients with steadily progressing disease
  • Follow-up every 6 months is recommended for patients with stable disease & annual follow-up for patients with stable disease after 1 year
  • Patients with ongoing pulmonary rehabilitation should be reassessed at 6- or 12-month intervals
  • Pulse oximetry measurement at rest & during exertion is recommended during follow-up (3-6 month intervals) to monitor for oxygenation status
    • Oxygen desaturation of <88% prompts supplemental oxygenation 
  • Screening for complications (pulmonary hypertension, pulmonary embolism, coronary artery disease, lung cancer) may be done every follow-up
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.

Christina Lau, 23 Jun 2020

Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.

Elvira Manzano, 12 Dec 2020
Having asthma or allergy does not make COVID-19 severe, a new study presented at ACAAI 2020 has shown.